Choosing an eCTD submissions vendor: Your complete checklist
September 3, 2025 Selecting the right electronic submission vendor for regulatory submissions to health authorities…
CertaraJanuary 28, 2022
A bird’s eye view on rare diseases: Key drug development considerations for thyroid eye disease
New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…
CertaraDecember 15, 2021
Dose Optimization Using Population PK for an Orphan Drug
RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…
CertaraNovember 17, 2021
Defining path-to-market strategy through a data-driven and scientific approach
How Certara supported a gene therapy manufacturer by using a selection of gateway and value…
CertaraOctober 28, 2021
The Scary Future of Rare Disease Management
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…
CertaraSeptember 23, 2021
Succeeding in value communication: Introduction
Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…
CertaraAugust 5, 2021
What is BaseCase?
Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…
CertaraJuly 20, 2021
Preparing for high stakes meetings; how to best convey a new drug’s value to payers
This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…
CertaraJune 18, 2021
